替比夫定对乙肝肝硬化患者血清HA、LN、CIV、PⅢNP的影响

Study on the effect of telbivudine on HA,LN,CIV and pCⅢ in patients with hepatitis B

目的:观察应用替比夫定(LDT)治疗对于代偿期乙肝肝硬化HA、PⅢNP、CIV、LN的影响,从而进一步探讨抗病毒治疗对于代偿期乙肝肝硬化肝纤维化逆转的可能性。方法:选择40例代偿期乙肝肝硬化患者,随机分为治疗组和对照组各20例。治疗组口服替比夫定600mg/d加护肝片5片/d,对照组20例口服护肝片5片/d,疗程均为24周。观察两组病人治疗后HA、PⅢNP、CIV、LN数值变化及HBV-DNA水平。结果:治疗组HBV-DNA检测不到率明显高于对照组(P<0.01),HA、PⅢNP、CIV、LN下降幅度与对照组有显著差异(P<0.05)。结论:应用替比夫定抗病毒治疗代偿期乙肝肝硬化,在抑制病毒同时,可以使肝纤维化指标明显下降。

Objective： to study the effect of telbivudine on the serum marker HA, LN, CIV and P Ⅲ NP in patients with hepatocirrhosis and to further explore its possibility of reversal of liver fibrosis with antivirus ther- apy. Methods：a total of 40 patients with hepatocirrhosis in hepatitis B were randomly divided into treatment group and control group. The treatment group was treated with telbivudine, 600mg each day, and liver--pro- tecting tablet, 5 tablets each day, for 24 weeks, while the control group was treated only with liver--protecting tablet, 5 tablets each day, for 24 weeks. Levels of HA, P Ⅲ NP, CIV, LA and HBV--DNA were observed af- ter treatment. Results：After therapy, the level of nonHBV--DNA in the treatment group is higher obviously than that in the control group （P〈0.01）. The levels of HA, P Ⅲ NP, CIV, LA in the treatment group de- clined apparently （P〈0.05）, compared with the control group, and there was an obvious difference. Conclu- sion：Therapy of antivirus with telbivudine has obvious activity against virus and it can descend serum index of liver fibrosis.